Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

We recently published a list of the 13 Best American Dividend Stocks to Buy According to Analysts. In this article, we are ...

Medifast, Inc. MED is likely to register a decrease in both top and bottom lines when it reports first-quarter 2025 earnings ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

People with type 2 diabetes taking the highest dose of Eli Lilly’s experimental drug orfoglipron lowered their blood sugar and lost 16 pounds on average after 40 weeks.

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

Dr. Bharti Shetye, also known as Dr. Abby, CEO and Physician Owner of Dr. Abby’s Weight Management Clinic, recently joined Gayle Guyardo, host of the global health and ...

A large population-based study found that GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is), two classes of ...

It’s time, Boston! 30,000 runners are taking the trek from Hopkinton to Boston for the 129th Boston Marathon. Here's what to know.